A prospective study of a protocol that reduces readmission after liver transplantation

Mark W. Russo, David M. Levi, Ruth Pierce, Vincent Casingal, Lon Eskind, Andrew deLemos, Paul A. Schmeltzer, Philippe J. Zamor – 26 February 2016 – Health care has shifted to placing priority on quality and value instead of volume. Liver transplantation uses substantial resources and is associated with high readmission rates. Our goal was to determine if a protocol designed to reduce readmission after liver transplant was effective.

Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation

Neil E. Crittenden, Laura A. Buchanan, Christina M. Pinkston, Barbra Cave, Ashutosh Barve, Luis Marsano, Craig James McClain, Christopher M. Jones, Michael R. Marvin, Eric G. Davis, Candice B. Kuns‐Adkins, Roberto Gedaly, Guy Brock, Malay B. Shah, Jens Rosenau, Matthew C. Cave – 25 February 2016 – Although combination simeprevir (SIM) plus sofosbuvir (SOF) is an approved regimen for genotype 1 chronic hepatitis C virus (HCV), data regarding its safety and efficacy in liver transplant recipients remain limited.

Subscribe to